Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

PTCT vs MTVA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PTCT Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 6–4 Matrix Metrics)

PTCT Overall Winner 6-Pillar Tally: PTCT 4 – 2 MTVA Matrix Metrics: PTCT 6 – 4 MTVA

As of Nov 20, 2026, PTC Therapeutics, Inc. (PTCT) is the stronger overall head-to-head candidate over MetaVia Inc. (MTVA) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PTCT carries a Unified Composite Score of 36.3/100 (SELL) at $56.42 (17.7x Forward P/E, 21.5% operating margin), whereas MTVA carries 48.0/100 (HOLD) at $1.01 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While MTVA currently prints a higher short-term Unified Composite Score (48.0/100 HOLD vs. PTCT 36.3/100 SELL), PTCT captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (21.5% vs. 0.0% operating margin) and revenue trajectory (+69.6% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: PTCT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.6); meanwhile MTVA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PTCT vs MTVA
PTCT NASDAQ Head-to-Head Winner
PTC Therapeutics, Inc.
Pharmaceutical Preparations
$56.42
-3.27% 1D
Market Cap $4.9B
TTM Revenue $1.16B
Forward P/E 17.7x
Beta / 30D Vol 0.83β · 58% Vol
Unified Composite Score
36.3 / 100 SELL
Tech 15.0 Fund 46.0 Flow 70.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.7%), weak momentum, RSI 34
RSI-14: 33.6 · SMA20: $62.85 · SMA50: $63.26
MTVA NASDAQ
MetaVia Inc. Common Stock
Pharmaceutical Preparations
$1.01
-5.61% 1D
Market Cap $7.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.30β · 166% Vol
Unified Composite Score
48.0 / 100 HOLD
Tech 40.0 Fund 60.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.2%), weak momentum, RSI 38
RSI-14: 38.1 · SMA20: $1.24 · SMA50: $1.40

6-Pillar Scorecard Institutional Category Breakdown (PTCT 4 – 2 MTVA)

Columns: Metric · PTCT · MTVA
1. Valuation Multiples PTCT
Forward P/E 17.7x N/M
Trailing P/E 18.0x N/M
PEG Ratio 0.81x N/M
EV / Revenue 4.3x N/M
2. Growth & Scale PTCT
Revenue Growth (YoY) +69.6% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $1.16B N/A
Market Cap $4.9B $7.2M
3. Profitability & Quality PTCT
Gross Margin 55.2% N/A
Operating Margin 21.5% 0.0%
Net Profit Margin -9.2% 0.0%
Return on Equity (ROE) -7740.1% -175.7%
4. Balance Sheet & Cash Flow MTVA
Cash Generation (TTM) -$41M -$15M
Cash Flow Margin -3.6% N/A
Net Cash / Leverage $127M Net Debt $14M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MTVA
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 52.7% (11th %ile) N/A (N/A)
Put/Call OI Skew 0.05x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat PTCT
OpEx & R&D Intensity 33.7% of Rev ($389M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PTCT (6) vs MTVA (4)
Institutional Metric PTCT MTVA Criterion Row Edge
Market Capitalization
Scale
$4.9B $7.2M Larger Scale PTCT
Trailing P/E Ratio
Valuation
18.0x N/M Lower Multiple PTCT
Forward P/E Ratio
Valuation
17.7x N/M Lower Multiple PTCT
Revenue Growth (YoY)
Growth
+69.6% +0.0% Higher Growth PTCT
Operating Margin (TTM)
Profitability
21.5% 0.0% Higher Margin PTCT
Net Profit Margin
Profitability
-9.2% 0.0% Higher Margin MTVA
Return on Equity (ROE)
Capital Efficiency
-7740.1% -175.7% Higher ROE MTVA
52-Week Range Position
Momentum
1% ($56–$91) 4% ($1–$13) Stronger Trend MTVA
Beta / 30D Volatility
Risk Regime
0.83β · 58% Vol 1.30β · 166% Vol Lower Realized Risk PTCT
Unified Institutional Score
Composite Signal
36.3 / 100 (SELL) 48.0 / 100 (HOLD) Higher Composite MTVA
Trailing 12M Revenue (USD)
Operating Scale
$1.16B N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
55.2% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.81x PEG · 4.3x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$41M ($127M Net Debt) -$15M ($14M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PTCT +16.84 pp
PTCT: -10.5% · MTVA: -27.34%
3M Horizon PTCT +13.39 pp
PTCT: -20.6% · MTVA: -33.99%
6M Horizon PTCT +55.76 pp
PTCT: -18.01% · MTVA: -73.77%
1Y Horizon MTVA +57.57 pp
PTCT: -25.37% · MTVA: +32.2%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PTCT vs MTVA. Trailing 12-month operating profitability (PTCT 21.5% vs MTVA 0.0%) and valuation multiples (PTCT 17.7x vs MTVA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

PTCT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.16B
Gross Margin55.2%
Op. Margin21.5%
ROE / Fwd P/E-7740.1% · 17.7x
MTVA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-175.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PTCT BREAKDOWN
95d in phase · OBV DISTRIBUTION
Current IV 52.7%
IV Percentile 11th %ile
Put/Call OI Skew 0.05x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact PTCT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MTVA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MTVA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PTCT Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $4.9B market capitalization and 21.5% operating margin.
OpEx & R&D Reinvestment 33.7% of Rev ($389M)
90D Engineering Disclosures 0 Published
MTVA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $7.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PTCT vs MTVA Key Questions & Quantitative Answers

As of Nov 20, 2026, PTC Therapeutics, Inc. (PTCT) is the stronger overall head-to-head candidate over MetaVia Inc. (MTVA) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PTCT carries a Unified Composite Score of 36.3/100 (SELL) at $56.42 (17.7x Forward P/E, 21.5% operating margin), whereas MTVA carries 48.0/100 (HOLD) at $1.01 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While MTVA currently prints a higher short-term Unified Composite Score (48.0/100 HOLD vs. PTCT 36.3/100 SELL), PTCT captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (21.5% vs. 0.0% operating margin) and revenue trajectory (+69.6% vs. +0.0% YoY). Technical & Structure Timing Caution: PTCT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.6); meanwhile MTVA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PTCT leads the Growth & Scale pillar: PTCT posts +69.6% YoY revenue growth and +0.0% YoY earnings growth on $1.16B TTM revenue (55.2% gross margin, 21.5% operating margin), compared with MTVA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, PTCT generates $1.16B in USD-normalized revenue versus N/A for MTVA. In operating R&D and SG&A reinvestment, PTCT deploys 33.7% of Rev ($389M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MTVA.

PTCT screens cheaper on headline valuation multiples. PTCT trades at 17.7x Forward P/E, 18.0x Trailing P/E, 0.81x PEG, and 4.3x EV/Revenue (-3.6% FCF margin), whereas MTVA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PTCT (-7740.1% ROE) versus MTVA (-175.7% ROE) capital efficiency.

In options market volatility and institutional positioning, PTCT carries 52.7% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.05x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.83β · 58% Vol realized risk). By comparison, MTVA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.30β · 166% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.